4.6 Article

Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications

Journal

OBSTETRICS AND GYNECOLOGY
Volume 127, Issue 3, Pages 468-473

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/AOG.0000000000001242

Keywords

-

Funding

  1. Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center

Ask authors/readers for more resources

OBJECTIVE: To estimate the frequency of unsuspected sarcoma identified postoperatively in women undergoing surgery for benign gynecologic indications at our institution. METHODS: Patients undergoing hysterectomy for benign gynecologic indications from 2000 to 2014 at our institution were identified. Patients who did not have a preoperative suspicion for malignancy and were found to have uterine sarcoma on pathology postoperatively were considered to have an occult uterine sarcoma. Relevant clinical and pathologic data were collected for this retrospective cohort study. RESULTS: A total of 10,119 hysterectomies for benign gynecologic indications were performed between 2000 and 2014. Among these, nine patients were found to have uterine sarcoma, with an overall rate 1 in 1,124 (95% confidence interval 1/592-1/2,457). These malignancies included five leiomyosarcomas, two endometrial stromal sarcomas, and two uterine adenosarcomas. Median age was 39 years (range 25-53 years). Among women found to have occult sarcoma, hysterectomy was performed as a primary indication for abnormal bleeding (77.8%) and leiomyomas (22.2%). Cases included six total abdominal hysterectomies, two total vaginal hysterectomies, and one supracervical hysterectomy. One case required manual morcellation during abdominal hysterectomy. Power morcellation was not used in any of the cases. CONCLUSION: In summary, occult uterine sarcoma occurs in 0.089% or 1 in 1,124 hysterectomies for benign indications in our population. The frequency is lower than the rate derived in earlier reports and by the U.S. Food and Drug Administration in their pooled analysis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?

Anna L. Beavis, Ting-Tai Yen, Rebecca L. Stone, Stephanie L. Wethington, Caitlin Carr, Ji Son, Laura Chambers, Chad M. Michener, Stephanie Ricci, Wesley C. Burkett, Debra L. Richardson, Allison-Stuart Staley, Susie Ahn, Paola A. Gehrig, Diogo Torres, Sean C. Dowdy, Mackenzie W. Sullivan, Susan C. Modesitt, Catherine Watson, Ashely Veade, Jessie Ehrisman, Laura Havrilesky, Angeles Alvarez Secord, Amy Loreen, Kaitlyn Griffin, Amanda Jackson, Akila N. Viswanathan, Leah R. Jager, Amanda N. Fader

GYNECOLOGIC ONCOLOGY (2020)

Article Oncology

Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion

Ji Son, Laura M. Chambers, Caitlin Carr, Chad M. Michener, Meng Yao, Anna Beavis, Ting-Tai Yen, Rebecca L. Stone, Stephanie L. Wethington, Amanda N. Fader, Wesley C. Burkett, Debra L. Richardson, Allison S. Staley, Susie Ahn, Paola A. Gehrig, Diogo Torres, Sean C. Dowdy, Mackenzie W. Sullivan, Susan C. Modesitt, Catherine Watson, Ashley Veade, Jessie Ehrisman, Laura Havrilesky, Angeles Alvarez Secord, Amy Loreen, Kaitlyn Griffin, Amanda Jackson, Akila Viswanathan, Stephanie Ricci

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)

Article Oncology

Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)

Krishnansu S. Tewari, Michael W. Sill, Bradley J. Monk, Richard T. Penson, David H. Moore, Heather A. Lankes, Lois M. Ramondetta, Lisa M. Landrum, Leslie M. Randall, Ana Oaknin, Mario M. Leitao, Eric L. Eisenhauer, Paul DiSilvestro, Linda Van Le, Michael L. Pearl, James J. Burke, Ritu Salani, Debra L. Richardson, Helen E. Michael, David W. Kindelberger, Michael J. Birrer

MOLECULAR CANCER THERAPEUTICS (2020)

Meeting Abstract Oncology

Phase I expansion study of P-cadherin-targeted 90Y-FF-21101 antibody in advanced chemorefractory colorectal and pancreatic-biliary cancers.

Devalingam Mahalingam, Vivek Subbiah, Taofeek K. Owonikoko, Susanna Varkey Ulahannan, Debra L. Richardson, Aparna Kalyan, Mary Frances Mulcahy, Catherine A. Wheeler, Satoshi Matsushima, Takeaki Suzuki, Ruth Ann Subach, Mary Johansen, Timothy Madden, Cheung Kin, David S. Wages

JOURNAL OF CLINICAL ONCOLOGY (2021)

Meeting Abstract Oncology

First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+cancers.

Alan Loh Ho, Marshall R. Posner, Jiaxin Niu, Siqing Fu, Rom S. Leidner, Alexander T. Pearson, Ki Y. Chung, Debra L. Richardson, Ding Wang, Agustin Pimentel, Jorge J. Nieva, Ari Rosenberg, Bharat Burman, Corinne Iacobucci, Xiaoping Qing, Andy Hwang, Kia Katchar, Katia Schlienger, Igor Matushansky, David G. Pfister

JOURNAL OF CLINICAL ONCOLOGY (2021)

Meeting Abstract Oncology

Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.

Debra L. Richardson, Erika P. Hamilton, Ana Oaknin, Leslie M. Randall, Susana N. Banerjee, Sara Kristina Taylor, Linda R. Mileshkin, Robert L. Coleman, Bradley J. Monk, Mansoor Raza Mirza, Patricia Bernardo, Rebecca Mosher, Valerie Malyvanh Jansen, Antonella Savarese, Toon Van Gorp, Radoslaw Madry, Isabelle Laure Ray-Coquard, Nicole Concin

JOURNAL OF CLINICAL ONCOLOGY (2021)

Meeting Abstract Oncology

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.

Camille Catherine Jackson, Leigh Cantrell, Britt Kristina Erickson, Kathleen N. Moore, Linda R. Duska, Debra L. Richardson, Lisa Michelle Landrum, Laura L. Holman, Joan L. Walker, Robert S. Mannel, Katherine M. Moxley, Lurdes Queimado, Kai Ding, Andrew Cohoon, Sara Vesely, Lauren E. Dockery

JOURNAL OF CLINICAL ONCOLOGY (2021)

Meeting Abstract Oncology

Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.

Filip Janku, Erika P. Hamilton, Cara Amanda Mathews, Christina Chu, Jennifer Robinson Diamond, John L. Hays, Rebecca Christian Arend, Massimo Cristofanilli, Andrea Jewell, William Reichmann, Keisuke Kuida, Haroun Achour, Rodrigo Ruiz-Soto, Debra L. Richardson

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Oncology

OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab

Melissa M. Hardesty, Thomas C. Krivak, Gail S. Wright, Erika Hamilton, Evelyn L. Fleming, Jimmy Belotte, Erika K. Keeton, Ping Wang, Divya Gupta, Aine Clements, Heidi J. Gray, Gottfried E. Konecny, Richard G. Moore, Debra L. Richardson

Summary: This study evaluated the safety and efficacy of Niraparib + bevacizumab as a first-line maintenance therapy for newly diagnosed advanced ovarian cancer patients. The results showed promising PFS outcomes and the safety profile was consistent with the monotherapy of these drugs.

GYNECOLOGIC ONCOLOGY (2022)

Review Oncology

Targeting NaPi2b in ovarian cancer

Susana Banerjee, Ronny Drapkin, Debra L. Richardson, Michael Birrer

Summary: This article discusses the research progress on NaPi2b as a novel biomarker for treatment and patient selection in ovarian cancer. NaPi2b is highly expressed in ovarian tumors and can be used for tumor mapping and therapeutic targeting. Clinical trial results have shown successful detection of NaPi2b in ovarian cancer patients, and it has the potential to elicit therapeutic responses.

CANCER TREATMENT REVIEWS (2023)

Article Pharmacology & Pharmacy

Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors

Xiaofei Zhou, Debra L. Richardson, Afshin Dowlati, Sanjay Goel, Solmaz Sahebjam, James Strauss, Sant Chawla, Ding Wang, Diane R. Mould, Vivek Samnotra, Douglas Faller, Karthik Venkatakrishnan, Neeraj Gupta

Summary: The study assessed the effect of pevonedistat on heart rate-corrected QT interval in cancer patients. The results showed that pevonedistat did not cause clinically relevant effects on heart rate or cardiac repolarization.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2023)

Editorial Material Obstetrics & Gynecology

Ocular toxicity and mitigation strategies for antibody drug conjugates in gynecologic oncology

Debra L. Richardson

Summary: Recently, two antibody drug conjugates have been approved by the FDA for the treatment of recurrent gynecologic malignancies. However, these new agents are associated with ocular toxicity. Fortunately, ocular toxicity can be prevented and mitigated by following recommended eye care strategies.

GYNECOLOGIC ONCOLOGY REPORTS (2023)

Meeting Abstract Oncology

Efficacy and safety of lucitanib plus nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).

Manish R. Patel, Vicky Makker, Ana Oaknin, Sandro Pignata, Floor Jenniskens Backes, Antonio Gonzalez Martin, Ramez Nassef Eskander, Bhavana Pothuri, Debra L. Richardson, Angeles Alvarez Secord, Els Van Nieuwenhuysen, Joyce F. Liu, Fernanda Musa, Richard T. Penson, Kenton Wride, Denise M. Lepley, Rachel Dusek, Teresa Cameron, Erika P. Hamilton, Nicole Concin

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+cancers

Siqing Fu, Lisle Nabell, Alexander T. Pearson, Rom Leidner, Douglas Adkins, Marshall R. Posner, Jorge J. Nieva, Debra L. Richardson, Agustin Pimentel, Sanjay Goel, Stuart J. Wong, Alan Loh Ho, Ari Rosenberg, Matthew H. Taylor, Raghad Abdul-Karim, Corinne Iacobucci, Xiaoping Qing, Kia Katchar, Katia Schlienger, David G. Pfister

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

An open-label, multicenter, phase Ib/II study of rebastinib in combination with paclitaxel in a dose-expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer.

Filip Janku, Erika Paige Hamilton, Christina Chu, Debra L. Richardson, Rebecca Christian Arend, Keisuke Kuida, Haroun Achour, Rodrigo Ruiz-Soto, John L. Hays

JOURNAL OF CLINICAL ONCOLOGY (2020)

No Data Available